Q-omics provides the consensus-scored MIR7-2 profile across patient tissues and cancer cell-line models. MIR7-2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MIR7-2 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, MIR7-2 RNA expression shows 11,208 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BRCA, THCA, and COAD as cancer lineages where MIR7-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR7-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR7-2 survival associations across molecular data types. MIR7-2 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR7-2 RNA expression–survival associations across cancer types. High MIR7-2 expression shows unfavorable associations in BRCA, ACC, THCA, THYM and CESC, but favorable associations in LGG. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for MIR7-2 RNA expression.
This table summarizes MIR7-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR7-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR7-2 shows lower tumor expression in THCA. The THCA box plot shows higher MIR7-2 RNA expression in normal versus tumor tissue (log2 FC = −1.423, t-test p < 0.001).
This table shows molecular features associated with MIR7-2 in patient tissues and cancer cell lines. In patient samples, MIR7-2 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
